• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Authors » Jason Mallo, DO

Articles by Jason Mallo, DO

Clinical Update

How to Diagnose Borderline Personality Disorder

January 1, 2025
Jason Mallo, DO
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

C. Jason Mallo, DO. Division Medical Director, Maine Medical Center Department of Psychiatry, Adult Outpatient Psychiatry. Assistant Clinical Professor, Tufts University School of Medicine.

Dr. Mallo has no financial relationships with companies related to this material.

We show you how to ask about borderline criteria and how to convey the diagnosis to the patient.


Read More
Alpha2Thumb.png

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

October 18, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
Read More
Alpha2Thumb.png

Alpha-2 Agonists Review: Clonidine (Kapvay) and Guanfacine (Intuniv), Non-Stimulant ADHD Medications

October 6, 2024
Jason Mallo, DO and Greg Malzberg, MD
In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.
Read More
shutterstock_2067560870_Prostock-studio.jpg
CARLAT WEBINAR

How to Diagnose Borderline Personality Disorder

January 22, 2024
Jason Mallo, DO

0.50 CME Credits. You do not need to be an expert in borderline personality to help your patients. Dr. Mallo will introduce tactics that can be applied in different treatment settings.


Read More

Hypothyroidism and Depression: Just How Related Are They?

June 1, 2022
Jason Mallo, DO
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

C. Jason Mallo, DO. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A landmark study puts a spotlight on whether patients can successfully taper off their antidepressant without relapsing.


Read More

Atomoxetine: Myths and Truths

September 10, 2021
Jason Mallo, DO
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jason Mallo, DO. Attending psychiatrist, Maine Medical Center, Portland, ME. Dr. Mallo has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
From ADHD to off-label uses, we detail how to dose atomoxetine, how pharmacogenomic testing affects it, and how it compares with stimulants and the other antidepressant for ADHD, viloxazine (Qelbree).
Read More

A Closer Look at Alpha-2 Agonists for ADHD

March 11, 2021
Jason Mallo, DO
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
C. Jason Mallo, DO. Attending Psychiatrist, Maine Medical Center, Portland, Maine. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Now that guanfacine ER (Intuniv) and clonidine ER (Kapvay) have gone generic, we review the 40-years of research that earned them FDA approval in ADHD. Along the way we’ll consider their off-label use in anxiety, addiction, insomnia, and self-harm. Plus: When to use the ER, the instant release, or the oft-forgotten transdermal patch.
Read More

E-Cigarettes vs Nicotine Replacement for Smoking Cessation

June 10, 2020
Jason Mallo, DO
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Jason Mallo, DO. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Quitting smoking remains extremely difficult. This multicenter randomized controlled trial evaluates the efficacy of using e-cigarettes compared to nicotine replacement among adults (average age 41) seeking help to quit smoking.
Read More

New Hope: CBT for Internet and Computer Game Addiction

February 11, 2020
Jason Mallo, DO
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Jason Mallo, DO Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Internet and computer game addictions represent difficult-to-define and difficult-to-treat conditions that are increasing in prevalence. To provide some guidance on treatment options, investigators tested short-term cognitive behavioral therapy in a randomized, controlled trial.
Read More

Polypharmacy in Schizophrenia

February 10, 2020
Jason Mallo, DO
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jason Mallo, DO. Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Polypharmacy is often practiced in schizophrenia, but you have to look hard to find any evidence that it helps. These two large-scale studies lend some empiric support to the practice, but also give us insights into how it could go wrong.
Read More
Previous 1 2 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.